单克隆 - Open Access .click

Results 101 to 110 of about 333,733 (143)

, 2010
本发明公开了一种抗诺氟沙星多克隆抗体及其制备方法和应用。该抗体是通过以下方法制备的：a)免疫原的制备：以诺氟沙星为半抗原，通过N-羟基琥珀酰亚胺活性酯法(NHS)将诺氟沙星与牛血清蛋白(BSA)偶联，得到免疫原；b)多克隆抗体的制备：将免疫原免疫动物，取动物血清，用免疫球蛋白A亲和层析法对血清进行纯化，最后获得的抗体，即为抗诺氟沙星多克隆抗体。该抗诺氟沙星多克隆抗体具有单一性高、灵敏度高、特异性强、并且能长期保存，能高效结合诺氟沙星的优点 ...
彭先芝 +4 more
core

[Expert consensus on the comprehensive management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma in China (2025)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Plasma Cell Disease Group +3 more
europepmc +1 more source

Olig2⁺ single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model. [PDF]

J Zhejiang Univ Sci B
Peng D +8 more
europepmc +1 more source

[Advances in single cell omics applications in mantle cell lymphoma]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Wang C, Zhang Q, Cao X.
europepmc +1 more source

[Eculizumab resistance caused by C5 gene polymorphism in a patient with paroxysmal nocturnal hemoglobinuria: a case report]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Zhou RQ +5 more
europepmc +1 more source

3A1-柔红霉素对急性T细胞白血病的效果与安全性初探

Zhongshan Daxue xuebao. Yixue kexue ban, 1996
应用单克隆抗体３Ａ１－柔红霉素结合物（３Ａ１－ＤＭ）临床治疗８例急性Ｔ淋巴细胞白血病患者。经初步验证，鼠源性单克隆抗体制备的导向药物输入人体内未发生严重过敏反应与毒副作用。疗程完毕后，以骨髓象为标准评价临床治疗效果，获完全缓解者３／８例（３７．５％），部分缓解４／８例（５０％），无效１／８例（１２．５％）例，总有效率达８７．５％。初步验证了微量导向药物在临床治疗中的效果。
doaj

131I-Anti-c-erb2 免疫导向治疗卵巢癌的实验研究

Zhongshan Daxue xuebao. Yixue kexue ban, 2004
【目的】观察放射性核素标记针对癌蛋白为靶点的单克隆抗体载体外对卵巢癌细胞的抑制作用。【方法】应用氯胺T法将131I和抗c-erb2单克隆抗体标记,取不同浓度的131I-Anti-c-erb2与SKOV3细胞共同培养,MTT法检测其对SKOV3细胞生长的抑制作用。【结果】体外单抗浓度为22.20mg/L时,131I-Anti-c-erb2的相对抑制率为64.85%,可以明显抑制SKOV3细胞,未标记的抗c-erb2单抗的相对抑制率为3.40%,对SKOV3细胞的生长几乎没有抑制作用。【结论】131I ...
doaj

[KMT2A-rearranged acute lymphoblastic leukemia with lineage switch following relapse: a case report and literature review]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Qiao ZQ, Shi YP, Hu LD.
europepmc +1 more source

[Role and mechanism of infrared thermography in early identification of necrosis risk in random-pattern flaps of mice]. [PDF]

Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi
Jiang XQ +5 more
europepmc +1 more source

[The risk and management strategies for second primary tumor after CAR-T cell therapy]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Li RN, Wang WY, Yang F, Zhang LL, Shi J.
europepmc +1 more source

单克隆抗体
medicine general
抗体

pathology